
French firms Servier and small biopharma cancer specialist Cellectis have signed a deal to develop and commercialise one drug targeting …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

